Project Grant HT9425261E246
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $1.23 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2025, with a completion date of September 29, 2029. The award supports research to validate CD46 as a promising biomarker in advanced prostate cancer, aligning with the DHA's mission to transform healthcare for service members and the...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,226,730 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2029. The award funds research investigating the canonical Polycomb Repressive Complex 1 (cPRC1) as an intrinsic mechanism of resistance to enzalutamide in advanced prostate cancer. This hypothesis-driven research initiative...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.97M Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports the development of CD46-targeted antibody fragment radiopharmaceutical therapy for prostate cancer treatment. This research initiative represents a translational medicine effort to advance diagnostic and...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Regents of the University of California, San Francisco a $750,000 project grant under the Military Medical Research and Development program (CFDA 12.420) effective March 1, 2026, through February 28, 2029. The research project, titled "Use of Dimeric Immunoglobulin A to Treat Breast Cancer," will be conducted at UCSF's San Francisco facility. This award supports hypothesis-driven biomedical research...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $328,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2025, through June 30, 2027. The award funds research on intracranial drug delivery strategies targeting skull bone marrow to generate antitumoral myeloid cell immune responses against glioblastoma. This research initiative represents UCSF's...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,054,812 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective August 15, 2026, through August 14, 2030. This award supports biochemical and structural targeting research focused on GAQ-mutant melanoma, a specific melanoma subtype. The research initiative will be conducted at UCSF's San Francisco facility and represents the...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $1.4 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through July 31, 2029. The award supports research investigating metabolic mechanisms of resistance to mutant isocitrate dehydrogenase (IDH) inhibition in gliomas. This hypothesis-driven biomedical research initiative aligns with the...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $1,620,505 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026, through May 31, 2029. The award supports research and development services focused on novel mitochondrial metabolism inhibitors for aggressive and treatment-resistant MYC-high breast cancers. The research will be conducted at UCSF's San Francisco,...
- This $1,211,127 Project Grant awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a research project by the University of California, San Francisco (UCSF) to investigate the importance of immune responses to prostate tumor antigens primed by a combination of radiation and immunotherapy. The 4-year project aims to advance understanding of how to leverage the body's immune system to improve treatments for prostate cancer. As...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.148 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2028. The award funds research focused on "Targeting and Imaging Vitamin B5 Metabolism in Diffuse Midline Gliomas," a three-year biomedical research initiative designed to advance understanding of metabolic...
The Regents of the University of California, San Francisco (UCSF) received a $1.7 million project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on July 1, 2026, with completion scheduled for June 30, 2029. The grant supports research to develop PVRL2 (poliovirus receptor-related 2) as a therapeutic target and biomarker for prostate cancer immunotherapy. This three-year initiative will advance biomedical research and development activities aimed at transforming healthcare for service members and the American public through innovative therapeutic solutions in cancer immunotherapy. UCSF's research team will conduct hypothesis-driven investigations to identify and validate PVRL2's potential role in prostate cancer treatment response and prognosis, with research activities conducted at the institution's San Francisco, California facility. The deliverables encompass basic and translational research services, biomarker discovery, and therapeutic development activities consistent with the DHA's funding priorities in cancer research and precision medicine. As an established academic medical center with extensive federal research capabilities, UCSF will leverage its scientific expertise and infrastructure to advance this oncology research initiative within the Military Medical Research and Development program's emphasis on novel cancer immunotherapy approaches.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.7m | 5/27/26 |